1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)
Jonathan W. Riess(University of California Davis Medical Center), Dermot T. McDowell(Galecto (Denmark)), Shane O’Neill(Royal College of Surgeons in Ireland), Ayako Wakatsuki Pedersen(Newcastle upon Tyne Hospitals NHS Foundation Trust), Peter H. Shaw(Velindre NHS Trust), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), James Spicer(King's College London), J. Rubio Perez(Hospital Universitario Fundación Jiménez Díaz), E. Ehrnrooth(Boehringer Ingelheim (Germany)), Ezra E.W. Cohen(Moores Cancer Center), L. Medina Rodríguez(Instituto de Investigación Biomédica de Málaga)
Cited by 2
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805
siRNA-directed inhibition of HIV-1 infection
|Nature Medicine|2002|777